BankM sets Pentixapharm price target at EUR 12.24, keeps buy rating

• BankM set a Buy rating on Pentixapharm, citing a completed rights issue that it says strengthens talks with strategic partners.
• BankM set a 12-month price target of EUR 12.24.
• Funding raised totals about EUR 17 million from the equity raise, alongside EUR 18.5 million from an Eckert & Ziegler convertible bond agreement.
• BankM said the roughly EUR 35.5 million in available funds should support financing of the PANDA Phase 3 study.
• The report cited a 65.5% empirical probability of successful approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26264) on July 22, 2026, and is solely responsible for the information contained therein.